Zhu Yan, Zeng Fei, Lan Mei-Juan, Liang Jiang-Shu-Yuan, Cai Ling-Yun, Gu Pei-Pei, Guo Lu-Yao
Department of Nursing, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
J Thorac Dis. 2024 Apr 30;16(4):2216-2224. doi: 10.21037/jtd-23-1709. Epub 2024 Apr 29.
Extracorporeal membrane oxygenation (ECMO) has recently emerged as a critical support system for lung function in patients awaiting lung transplantation. This meta-analysis investigates the prognostic factors of lung transplantation following ECMO bridging therapy.
A comprehensive search was conducted in PubMed, Cochrane Library, Embase, CINAHL, Web of Science, Scopus, and ProQuest databases from inception to August 11, 2023. Included were cohort or case-control studies focusing on prognostic factors of lung transplantation with ECMO bridging therapy. Data extraction was performed independently, and study quality was assessed. A meta-analysis was carried out using RevMan 5.4 and Stata17.0 software to aggregate mortality rates and pertinent prognostic factors of ECMO as a bridge to lung transplantation.
The search identified eight trials encompassing 1,086 participants. The prognosis of patients undergoing lung transplantation with ECMO bridging was significantly associated with several factors: prolonged ECMO support [odds ratio 1.07, 95% confidence interval (CI): 1.02-1.12, I=77%], deterioration in liver and kidney function (odds ratio 3.62, 95% CI: 2.37-5.54, I=0%), and complications during ECMO (odds ratio 2.24, 95% CI: 1.45-3.44, I=5%).
Prolonged ECMO support, declining liver and kidney functions, and complications during ECMO are vital prognostic factors in lung transplantation following ECMO bridging therapy.
体外膜肺氧合(ECMO)最近已成为等待肺移植患者肺功能的关键支持系统。本荟萃分析调查了ECMO桥接治疗后肺移植的预后因素。
从数据库建立至2023年8月11日,在PubMed、Cochrane图书馆、Embase、CINAHL、Web of Science、Scopus和ProQuest数据库中进行了全面检索。纳入的是关注ECMO桥接治疗肺移植预后因素的队列或病例对照研究。独立进行数据提取,并评估研究质量。使用RevMan 5.4和Stata17.0软件进行荟萃分析,以汇总ECMO作为肺移植桥梁的死亡率和相关预后因素。
检索确定了八项试验,共1086名参与者。接受ECMO桥接肺移植患者的预后与几个因素显著相关:ECMO支持时间延长[比值比1.07,95%置信区间(CI):1.02 - 1.12,I = 77%]、肝肾功能恶化(比值比3.62,95% CI:2.37 - 5.54,I = 0%)以及ECMO期间的并发症(比值比2.24,95% CI:1.45 - 3.44,I = 5%)。
ECMO支持时间延长、肝肾功能下降以及ECMO期间的并发症是ECMO桥接治疗后肺移植的重要预后因素。